Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT). In addition, letermovir has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, and is under review in several countries, including Japan. This article summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT.

Hydroxypropyl beta Cyclodextrin is an ideal solubilizer and excipient for injection.

1.Solubilization and solubilization, dissolve insoluble drugs, improve the solubility of Active ingredient of oily drugs, target drug delivery and protect the effectiveness of drug ingredients.

2.Improve the bioavailability of drugs to increase their efficacy or reduce their dosage.

3.Adjust or control the release rate of drugs to reduce drug toxicity and side effects.

4.Cover up bad odors.